GP681 tablet

DRUG3 trials

Sponsors

Jiangxi Qingfeng Pharmaceutical Co. Ltd.

Conditions

Healthy ParticipantsInfluenza

Phase 1

Evaluation the Safety and Tolerance of GP681 Tablets in Healthy Subjects

CompletedNCT04729764

Jiangxi Qingfeng Pharmaceutical Co. Ltd.Influenza

Start: 2020-08-27End: 2020-12-15Updated: 2021-01-28

Study to Assess Relative Bioavailability of GP681 Formulations in Healthy Chinese Male Subjects

CompletedNCT06678542

Jiangxi Qingfeng Pharmaceutical Co. Ltd.Healthy Participants

Start: 2024-09-27End: 2025-02-16Updated: 2025-03-14

Phase 2

A Clinical Study on the Safety and Efficacy of GP681 Tablets in the Treatment of Uncomplicated Acute Influenza

CompletedNCT04736758

Jiangxi Qingfeng Pharmaceutical Co. Ltd.Influenza

Start: 2021-01-08End: 2021-12-18Updated: 2022-07-26

Related Papers

A first-in-human phase I study to evaluate the safety, tolerability, and pharmacokinetics of a novel anti-influenza agent suraxavir marboxil in healthy Chinese subjects

Antimicrobial Agents and Chemotherapy2025-09-301 citations

Efficacy and safety of single-dose suraxavir marboxil tablet in the treatment of acute uncomplicated influenza in adults: a multi-centre, randomized, double-blind, placebo-controlled phase 2 clinical trial.

2025-01-252 citations